AAPL   398.20 (+3.78%)
FB   247.19 (+0.87%)
GOOGL   1,560.37 (+1.39%)
NVDA   428.66 (+2.26%)
CGC   18.14 (+4.13%)
BABA   261.18 (+0.07%)
AMD   57.13 (+2.24%)
GILD   77.20 (+1.15%)
DIS   119.77 (+0.36%)
NFLX   564.97 (+2.96%)
BAC   24.07 (+0.21%)
BA   176.53 (-1.07%)
AAPL   398.20 (+3.78%)
FB   247.19 (+0.87%)
GOOGL   1,560.37 (+1.39%)
NVDA   428.66 (+2.26%)
CGC   18.14 (+4.13%)
BABA   261.18 (+0.07%)
AMD   57.13 (+2.24%)
GILD   77.20 (+1.15%)
DIS   119.77 (+0.36%)
NFLX   564.97 (+2.96%)
BAC   24.07 (+0.21%)
BA   176.53 (-1.07%)
AAPL   398.20 (+3.78%)
FB   247.19 (+0.87%)
GOOGL   1,560.37 (+1.39%)
NVDA   428.66 (+2.26%)
CGC   18.14 (+4.13%)
BABA   261.18 (+0.07%)
AMD   57.13 (+2.24%)
GILD   77.20 (+1.15%)
DIS   119.77 (+0.36%)
NFLX   564.97 (+2.96%)
BAC   24.07 (+0.21%)
BA   176.53 (-1.07%)
AAPL   398.20 (+3.78%)
FB   247.19 (+0.87%)
GOOGL   1,560.37 (+1.39%)
NVDA   428.66 (+2.26%)
CGC   18.14 (+4.13%)
BABA   261.18 (+0.07%)
AMD   57.13 (+2.24%)
GILD   77.20 (+1.15%)
DIS   119.77 (+0.36%)
NFLX   564.97 (+2.96%)
BAC   24.07 (+0.21%)
BA   176.53 (-1.07%)
Log in

LON:AMYTAmryt Pharma Share Price, Forecast & News

GBX 180
-7.50 (-4.00 %)
(As of 07/13/2020 01:00 AM ET)
Add
Compare
Today's Range
180
Now: GBX 180
183
50-Day Range
106
MA: GBX 143.65
196
52-Week Range
12.38
Now: GBX 180
202
Volume126,805 shs
Average Volume184,629 shs
Market Capitalization£278.10 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Amryt Pharma plc, a commercial stage pharmaceutical company, focuses on the acquisition, development, and commercialization of medicines for the treatment of rare and orphan diseases. The company operates through two segments, Commercial and Research and Development. It offers Lojuxta (lomitapide), a drug used to treat a rare life-threatening disease Homozygous Familial Hypercholesterolaemia; and a range of dermo cosmetic products under the Imlan brand. Its products in development includes AP101 (Oleogel-S10), a prescription medicine used for the treatment of partial-thickness wounds in adults, which is in Phase III clinical trial; and AP102, a somatostatin analogue peptide medicine, which is in pre-clinical stage for patients with rare neuoendocrine diseases, such as acromegaly; and AP103, a gene therapy product line. The company operates in European Economic Area, the Middle East, North Africa, Turkey, Israel, and Switzerland. Amryt Pharma plc is based in London, the United Kingdom.
Read More
Amryt Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.63 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-34155730

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£98.16 million
Cash FlowGBX 39.76 per share
Book ValueGBX 65.50 per share

Profitability

Miscellaneous

Employees41
Market Cap£278.10 million
Next Earnings Date8/6/2020 (Estimated)
OptionableNot Optionable

Receive AMYT News and Ratings via Email

Sign-up to receive the latest news and ratings for AMYT and its competitors with MarketBeat's FREE daily newsletter.

Amryt Pharma (LON:AMYT) Frequently Asked Questions

How has Amryt Pharma's stock been impacted by COVID-19 (Coronavirus)?

Amryt Pharma's stock was trading at GBX 104 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AMYT stock has increased by 73.1% and is now trading at GBX 180. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amryt Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amryt Pharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Amryt Pharma.

When is Amryt Pharma's next earnings date?

Amryt Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Amryt Pharma.

Has Amryt Pharma been receiving favorable news coverage?

News stories about AMYT stock have been trending very negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amryt Pharma earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Amryt Pharma.

Who are some of Amryt Pharma's key competitors?

What other stocks do shareholders of Amryt Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include Chubb (CB), The Parkmead Group (PMG), Himax Technologies (HIMX), Atalaya Mining (ATYM), BK IRELAND GRP/ADR (BKRIY), Concepta (CPT), Faroe Petroleum (FPM), Vectura Group (VEC), Xcite Energy (XEL) and BowLeven (BLVN).

Who are Amryt Pharma's key executives?

Amryt Pharma's management team includes the following people:
  • Dr. Joseph Wiley, Founder, CEO & Exec. Director (Age 48)
  • Mr. Rory Nealon, CFO, COO, Company Sec. & Exec. Director (Age 51)
  • Dr. Tobias Zahn, Head of Clinical Operations
  • Dr. Mark Sumeray, Chief Medical Officer (Age 53)
  • Mr. David Allmond, Chief Commercial Officer

What is Amryt Pharma's stock symbol?

Amryt Pharma trades on the London Stock Exchange (LON) under the ticker symbol "AMYT."

How do I buy shares of Amryt Pharma?

Shares of AMYT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Amryt Pharma's stock price today?

One share of AMYT stock can currently be purchased for approximately GBX 180.

How big of a company is Amryt Pharma?

Amryt Pharma has a market capitalization of £278.10 million and generates £98.16 million in revenue each year. Amryt Pharma employs 41 workers across the globe.

What is Amryt Pharma's official website?

The official website for Amryt Pharma is www.amrytpharma.com.

How can I contact Amryt Pharma?

Amryt Pharma's mailing address is Ivybridge House, 1 Adam Street, LONDON, WC2N 6LE, United Kingdom. The company can be reached via phone at +44-20-34155730.

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.